Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00131963 · ClinicalTrials.gov registry record
A Pharmacogenomics Study for Breast Cancer Patients Undergoing Adjuvant Chemotherapy With Doxorubicin (A)/Cyclophosphamide ©) and/or Weekly Paclitaxel
A clinical trial, sponsored by Duke University.
- Completed
- Registry status
- 94
- Enrollment target
NCT00131963 is a clinical trial that has completed, run by Duke University. The registered enrollment target is 94 participants.
The verdict
NCT00131963 has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- 94 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy, such as doxorubicin, cyclophosphamide, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. Giving chemotherapy after surgery may kill any tumor cells that remain after surgery. PURPOSE: This phase II trial is studying how well doxorubicin, cyclophosphamide, and/or paclitaxel work in treating women with nonmetastatic breast cancer.
Interventions
- DRUG cyclophosphamide
- DRUG doxorubicin
- DRUG paclitaxel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 94 participants |
| Start Date | 2003-10 |
| Est. Completion | 2014-10 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00131963
The ClinicalTrials.gov registry entry for NCT00131963 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 94 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which cyclophosphamide is the first listed.
NCT00131963 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00131963 about?
NCT00131963 is a clinical study titled "A Pharmacogenomics Study for Breast Cancer Patients Undergoing Adjuvant Chemotherapy With Doxorubicin (A)/Cyclophosphamide ©) and/or Weekly Paclitaxel". RATIONALE: Drugs used in chemotherapy, such as doxorubicin, cyclophosphamide, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. Givin...
What is the current status of trial NCT00131963?
This trial is currently completed. The enrollment target is 94 participants. The study started on 2003-10. Estimated completion is 2014-10.
What interventions are being tested in trial NCT00131963?
The interventions under investigation include: cyclophosphamide (DRUG), doxorubicin (DRUG), paclitaxel (DRUG).
Who is sponsoring clinical trial NCT00131963?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.